LOS ANGELES, CA--(Marketwired - Jun 17, 2013) - MMRGlobal, Inc. (
The 4medica Meaningful Use Certified cloud-based EMR system is comparable to the best of physician EMR systems. 4medica comes bundled with a full-scale practice management solution, scheduling, mobile access and two-way communications to the MyMedicalRecords PHR. 4medica is also already connected to hundreds of laboratories, radiology centers and hospitals, which simplifies the initial startup for any practice. In addition, MMR and 4medica have already deployed solutions for state labs and other organizations including one that provides healthcare to more than 100,000 employee patients.
4medica already manages day to day laboratory results for more than 40,000 physicians. As a result, physicians' data will most likely be instantly available upon login to the EMR system. Unlike other cloud EMR packages, 4medica's user-friendly note writer is built around a word processor with customizable specialty templates, further simplifying training and integration to a practice.
MMRGlobal also offers physicians and their patients protection under its million dollar Cyber Liability Insurance Policy, which, among other things, protects healthcare professionals using the Company's MMRPro document management and imaging system to defend themselves in the event of a violation of the expanded HIPAA regulations under the Health Information Technology for Economic and Clinical Health Act (HITECH). The underlying Cyber Liability policy is underwritten by an A-rated insurance company by A.M. Best to cover damages arising from the use and deployment of the Company's personal and professional health record products and services. The coverage extends to MMRGlobal's corporate clients that offer MMR's products and services as an employee benefit and to individuals who sign up to receive MMR's services over the Internet.
MMR's Health Information Technology products and services are covered under the Company's Patent Portfolio which includes seven issued U.S. patents -- U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240 -- as well as additional applications and continuation applications including nearly 400 claims. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel, and European nations. The Company's health IT patent portfolio was the subject of a May 2, 2013 report on Personal Health Records that concluded that the value of the Company's U.S. patents could reach between $800 million to $1.1 billion in revenue (available at http://michaelbass.com/PDF/Patent_Valuation.pdf).
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. The MMR Stimulus Program is subject to the terms and conditions of the MMR Stimulus Physician Agreement. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
All statements in this press release that are not strictly historical in nature, including, but not limited to, the MMR Stimulus Program, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMRGlobal's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission, including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
- intellectual property
Public Communications Co.